Grey Matters Health Inc. (AGNPF)
Grey Matters Health, Inc. is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them into new human trials, developing new formulations and seeking new regulatory approvals in global markets. It specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing. The company was founded on January 22, 2015 and is headquartered in Vancouver, Canada.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Grey Matters Health Inc.
Trials need funding. See this company's dilution risk and cash position.
- Phase 2/3Completed
Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease
NP-120 (Ifenprodil)
COVID
NCT04382924Enrollment168StartAug 2020Primary CompletionDec 2020CompletionJan 2021 - Phase 2Completed
Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough
Ifenprodil
Idiopathic Pulmonary Fibrosis
NCT04318704Enrollment20StartJul 2020Primary CompletionMay 2022CompletionMay 2022 - Phase 1Active, not recruiting
Single and Repeat Doses of DMT in Healthy Subjects
N,N-Dimethyltryptamine, Placebo
Stroke
NCT05559931Enrollment60StartJan 2023Primary CompletionMar 2026est.CompletionMar 2026est. - ObservationalWithdrawn
Infection Detection by Breath Analysis
-
Infection, Community-Acquired, Communicable Disease +1
NCT02981550Enrollment0StartNov 2016Primary CompletionNov 2017est.CompletionNov 2018est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 2/3 | Completed | NP-120 (Ifenprodil) | NCT04382924 |
| Phase 2 | Completed | Ifenprodil | NCT04318704 |
| Phase 1 | Active, not recruiting | N,N-Dimethyltryptamine, Placebo | NCT05559931 |
| Observational | Withdrawn | - | NCT02981550 |